The Parkinson’s Progression Markers Initiative (PPMI) is a landmark observational clinical study to comprehensively evaluate cohorts of significant interest using advanced imaging, biologic sampling and clinical and behavioral assessments to identify biomarkers of Parkinson’s disease progression.
PPMI is taking place at clinical sites in the United States, Europe, Israel, and Australia. Data and samples acquired from study participants will enable the development of a comprehensive Parkinson’s database and biorepository, which is currently available to the scientific community to conduct field-changing research.
PPMI is made possible by the concerted efforts of a number of collaborators. This study is sponsored by The Michael J. Fox Foundation for Parkinson’s Research.
Learn more about Who We Are.
In June of 2016, The Michael J. Fox Foundation challenged data scientists and computational analysts to work with PPMI’s unprecedented collection of open-access clinical, molecular, and imaging data to answer two fundamental questions about Parkinson’s disease: what are the subtypes of the disease, and what baseline factors predict disease progression? In total, forty researchers submitted […]
Today The Michael J. Fox Foundation (MJFF) announced a challenge asking data scientists and computational analysts to work with researchers to answer fundamental questions about Parkinson’s that limit our understanding and slow drug testing. The PPMI Data Challenge offers $25,000 each to two teams that develop models to answer either: • What factors at baseline predict […]
The 2016 PPMI annual meeting took place on May 4-5 in New York City. The meeting brought together 175 PPMI stakeholders from around the world, including PPMI leadership, site principal investigators, site coordinators and industry partners. During the two day meeting, there was discussion of the data coming out of PPMI to date, plans for the […]
On March 11, Dr. Mark Frasier, Senior Vice President at the Michael J. Fox Foundation, shared an update on the PPMI study. Dr. Frasier summarized some of the key accomplishments of PPMI to date.
Many patients with Parkinson’s Disease (PD) develop mild cognitive impairment (MCI) or dementia. Identifying biomarkers for cognitive impairment could be instrumental in facilitating both early diagnosis of MCI and developing new cognitive-enhancing treatments. New research using PPMI data published in the Journal of Parkinson’s Disease indicates that lower concentrations of α-synuclein in cerebrospinal fluid (CSF) is associated with reduced performance on several cognitive tests.